Business, energy, technology, markets and global industry news from Business News Today

T-cell engagers

PharmaDeviceNews T-cell engagers
Representative image of advanced autoimmune drug research, reflecting UCB’s proposed acquisition of Candid Therapeutics and the rising focus on T-cell engager therapies.
Pharma & Biotech

Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?

UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.

Read More
Pharma & Biotech

Vir Biotechnology’s VIR-5500 tests whether dual-masked T-cell engagers can finally work in metastatic prostate cancer

Vir Biotechnology’s VIR-5500 shows early promise in metastatic prostate cancer. Find out what changes, what remains uncertain, and what comes next.

Read More